Evidence map›Paper›PMID 40583736›Full record

ArticleThoracic cancer2025

Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.

Ayako Shiono, Hisao Imai, Kyoichi Kaira, Takanori Abe, Yuki Sato, Ken Yamamoto, Hiroki Watanabe, Yuko Tsuchiya-Kawano, Akihiro Tamiya, Takashi Osaki and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ayako ShionoDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.ORCID https://orcid.org/0000-0001-6546-3864
Hisao ImaiDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.ORCID https://orcid.org/0000-0003-3097-4255
Kyoichi KairaDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.ORCID https://orcid.org/0000-0001-5548-7686
Takanori AbeDepartment of Radiation Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.ORCID https://orcid.org/0000-0001-6209-9446
Yuki SatoDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Ken YamamotoDivision of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Hyogo, Japan.ORCID https://orcid.org/0009-0006-1536-7640
Hiroki WatanabeDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Niigata, Japan.
Yuko Tsuchiya-KawanoDepartment of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan.
Akihiro TamiyaDepartment of Internal Medicine, NHO Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan.
Takashi OsakiDepartment of Respiratory Medicine, NHO Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Noriko YanagitaniDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Shigeru TanzawaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
Toshiyuki SumiDepartment of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, Japan.ORCID https://orcid.org/0000-0002-2540-5878
Kohei YoshimineDepartment of Respiratory Medicine, Iizuka Hospital, Iizuka, Fukuoka, Japan.
Yohei MatsuiDepartment of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Satoshi EndoDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Gunma, Japan.
Kazuhiko ShibataDivision of Medical Oncology, Department of Medicine, Kouseiren Takaoka Hospital, Takaoka, Toyama, Japan.
Shinnosuke TakemotoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.ORCID https://orcid.org/0000-0003-0373-0618
Yosuke MiuraDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Yoshiaki NagaiDepartment of Respiratory Medicine, Jichi Medical University, Saitama Medical Center, Saitama, Saitama, Japan.ORCID https://orcid.org/0000-0001-9466-8324
Junichi NakagawaDepartment of Respiratory Medicine, NHO Takasaki General Medical Center, Takasaki, Gunma, Japan.
Takeshi TsudaDivision of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

main problemThe efficacy and safety of platinum-based chemotherapy with programmed death-1 (PD-1) blockade after chemoradiotherapy (CRT) for the treatment of limited disease (LD) small cell lung cancer (SCLC) is unknown. This study aimed to assess the effectiveness and tolerability of platinum-based chemotherapy with PD-1 blockade in patients with recurrent LD-SCLC after CRT.

methodsThis retrospective study analyzed 66 patients who experienced recurrence after CRT for LD-SCLC and received platinum-based chemotherapy with PD-1 blockade therapy between August 2019 and September 2020 at 19 Japanese institutions. Clinical efficacy was assessed according to response rate, survival, and toxicity.

resultsThe overall response rate was 53.0% (95% confidence interval [CI], 48.9-65.0), and the disease control rate was 78.7% (95% CI, 68.9-88.5). The median progression-free survival and overall survival periods were 5.9 (95% CI, 4.7-7.3) months and 24.9 (95% CI, 16.8-28.1) months, respectively. The frequencies of grade ≥ 3 hematological adverse events were as follows: leukopenia, 47.0%; neutropenia, 65.2%; and febrile neutropenia, 8.3%. There was no treatment-related death.

conclusionsChemoimmunotherapy is a feasible and effective treatment for recurrent disease after CRT in patients with LD-SCLC, providing a new potential option for the pharmacological management of these patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsPlatinumProgrammed Cell Death 1 ReceptorSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesPlatinumProgrammed Cell Death 1 Receptorchemoradiotherapylimited disease small cell lung cancerPD‐1 blockaderecurrenceretrospective

Identifiers

PMID40583736
PMCPMC12207248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.